Streetbeat News

CERO

CERo Therapeutics Holdings, Inc.

https://www.cero.bio

Industry

Biotechnology

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Open

1.95

Mkt cap

5.4M

Volume

462K

High

1.98

P/E Ratio

-0.02

52-wk high

1095.00

Low

1.57

Div yield

N/A

52-wk low

1.57

CERo Therapeutics Holdings, Inc. has reported an increased cash balance and progress with its Nasdaq listing and the initiation of a Phase 1 trial, indicating a strong start for 2025.

Portfolio Pulse from

February 06, 2025 | 1:30 pm

CERo Therapeutics Holdings, Inc. has appointed Chris Ehrlich as the CEO. He was previously serving as the Interim CEO. CERo is focused on advancing engineered T cell therapeutics.

Portfolio Pulse from

December 06, 2024 | 2:15 pm

CERo Therapeutics Holdings, Inc. has received FDA clearance to initiate Phase 1 clinical trials for its lead compound, CER-1236, targeting acute myelogenous leukemia. This marks a significant step for the company in advancing its immunotherapy treatments.

Portfolio Pulse from

November 15, 2024 | 2:00 pm

CERo Therapeutics Holdings, Inc. presented promising preclinical data for its lead compound CER-1236, showing its ability to kill ovarian cancer cells without toxicity. This was announced at the SITC 2024 Conference.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

CERo Therapeutics has received a delisting notice from Nasdaq due to non-compliance with the MVLS requirement. The company has requested a hearing to appeal the decision and plans to present a compliance plan. The outcome of the appeal is uncertain.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 9:11 pm

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has submitted a Complete Response Letter to the FDA regarding a clinical hold on its CERO-1236 product. The company has adjusted its clinical entry guidance to early 2025 and disclosed a cash balance of $3.2M as of September 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:05 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. VSee Health (VSEE) saw a notable increase of 66.5%, while GRI Bio (GRI) rose by 21.58%. On the downside, SAB Biotherapeutics (SABS) fell by 7.8%, and Healthcare Triangle (HCTI) decreased by 7.21%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 8:31 pm

In Wednesday's after-market session, several healthcare stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, MSP Recovery, and TC BioPharm, while 10x Genomics and Trinity Biotech were among the losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 8:31 pm

CERo Therapeutics shares are experiencing a decline following the announcement of a change in their Chief Financial Officer.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 5:01 pm

CERo Therapeutics has appointed Al Kucharchuk as its new Chief Financial Officer. This leadership change could influence the company's financial strategies and operations.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.